financetom
Business
financetom
/
Business
/
Adhesives maker H.B. Fuller Q3 adjusted profit edges above expectations
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Adhesives maker H.B. Fuller Q3 adjusted profit edges above expectations
Sep 24, 2025 1:23 PM

Overview

* H.B. Fuller ( FUL ) fiscal Q3 revenue declines 2.8%, slightly below analyst expectations, per LSEG data

* Adjusted EPS for fiscal Q3 rises 12% and edges past analyst estimates

* Adjusted EBITDA increases 3% yr/yr, surpassing analyst expectations

Outlook

* Company expects fiscal 2025 net revenue to decline 2% to 3%

* H.B. Fuller ( FUL ) sees fiscal 2025 adjusted EBITDA at $615 mln to $625 mln

* Company anticipates fiscal 2025 adjusted EPS of $4.10 to $4.25

* H.B. Fuller ( FUL ) expects fiscal 2025 cash flow from operations of $275 mln to $300 mln

Result Drivers

* PRICING AND COST ACTIONS - Adjusted gross profit margin increased by 190 basis points year-on-year, driven by favorable net pricing and raw material cost actions

* DIVESTITURE IMPACT - Adjusted for the flooring divestiture, net revenue was up 1.6% year-on-year

* COST REDUCTION - Targeted cost reduction efforts contributed to the increase in adjusted gross profit margin

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $892 mln $895.80

Revenue mln (6

Analysts

)

Q3 Beat $1.26 $1.24 (6

Adjusted Analysts

EPS )

Q3 Beat $69 mln $68.60

Adjusted mln (5

Net Analysts

Income )

Q3 Beat $171 mln $169.20

Adjusted mln (6

EBITDA Analysts

)

Q3 $288 mln

Adjusted

Gross

Profit

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the specialty chemicals peer group is "buy."

* Wall Street's median 12-month price target for H.B. Fuller Company ( FUL ) is $72.00, about 17.2% above its September 23 closing price of $59.62

* The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 13 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved